694 related articles for article (PubMed ID: 26171558)
21. Photo-induced crosslinking of prion protein oligomers and prions.
Piening N; Weber P; Högen T; Beekes M; Kretzschmar H; Giese A
Amyloid; 2006 Jun; 13(2):67-77. PubMed ID: 16911960
[TBL] [Abstract][Full Text] [Related]
22. Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds.
Phuan PW; Zorn JA; Safar J; Giles K; Prusiner SB; Cohen FE; May BCH
J Gen Virol; 2007 Apr; 88(Pt 4):1392-1401. PubMed ID: 17374787
[TBL] [Abstract][Full Text] [Related]
23. Metabolic aspects of prion diseases: an overview.
Vranac T; Bresjanac M
Curr Drug Targets; 2010 Oct; 11(10):1207-17. PubMed ID: 20840065
[TBL] [Abstract][Full Text] [Related]
24. Prion protein functions and dysfunction in prion diseases.
Sakudo A; Ikuta K
Curr Med Chem; 2009; 16(3):380-9. PubMed ID: 19149584
[TBL] [Abstract][Full Text] [Related]
25. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein.
Liemann S; Glockshuber R
Biochemistry; 1999 Mar; 38(11):3258-67. PubMed ID: 10079068
[TBL] [Abstract][Full Text] [Related]
26. Prion protein-Semisynthetic prion protein (PrP) variants with posttranslational modifications.
Hackl S; Becker CFW
J Pept Sci; 2019 Oct; 25(10):e3216. PubMed ID: 31713950
[TBL] [Abstract][Full Text] [Related]
27. Residue-specific mobility changes in soluble oligomers of the prion protein define regions involved in aggregation.
Glaves JP; Ladner-Keay CL; Bjorndahl TC; Wishart DS; Sykes BD
Biochim Biophys Acta Proteins Proteom; 2018 Sep; 1866(9):982-988. PubMed ID: 29935976
[TBL] [Abstract][Full Text] [Related]
28. Sialylation of the prion protein glycans controls prion replication rate and glycoform ratio.
Katorcha E; Makarava N; Savtchenko R; Baskakov IV
Sci Rep; 2015 Nov; 5():16912. PubMed ID: 26576925
[TBL] [Abstract][Full Text] [Related]
29. High-resolution structure of infectious prion protein: the final frontier.
Diaz-Espinoza R; Soto C
Nat Struct Mol Biol; 2012 Apr; 19(4):370-7. PubMed ID: 22472622
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
Viruses; 2019 May; 11(5):. PubMed ID: 31083283
[TBL] [Abstract][Full Text] [Related]
31. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding.
Saborio GP; Permanne B; Soto C
Nature; 2001 Jun; 411(6839):810-3. PubMed ID: 11459061
[TBL] [Abstract][Full Text] [Related]
32. Truncated PrP(c) in mammalian brain: interspecies variation and location in membrane rafts.
Laffont-Proust I; Hässig R; Haïk S; Simon S; Grassi J; Fonta C; Faucheux BA; Moya KL
Biol Chem; 2006 Mar; 387(3):297-300. PubMed ID: 16542151
[TBL] [Abstract][Full Text] [Related]
33.
Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
[TBL] [Abstract][Full Text] [Related]
34. Evolving views in prion glycosylation: functional and pathological implications.
Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
[TBL] [Abstract][Full Text] [Related]
35. PrP(Sc)-specific antibodies do not induce prion disease or misfolding of PrP(C) in highly susceptible Tga20 mice.
Määttänen P; Taschuk R; Ross L; Marciniuk K; Bertram L; Potter A; Cashman NR; Napper S
Prion; 2013; 7(5):434-9. PubMed ID: 24105298
[TBL] [Abstract][Full Text] [Related]
36. Monitoring prion protein stability by NMR.
Julien O; Graether SP; Sykes BD
J Toxicol Environ Health A; 2009; 72(17-18):1069-74. PubMed ID: 19697241
[TBL] [Abstract][Full Text] [Related]
37. The pH-triggered conversion of the PrP(c) to PrP(sc.).
Zhou GP; Huang RB
Curr Top Med Chem; 2013; 13(10):1152-63. PubMed ID: 23647538
[TBL] [Abstract][Full Text] [Related]
38. Alkylating antitumor drug mechlorethamine conceals a structured PrP domain and inhibits in vitro prion amplification.
Zhou X; Bi H; Wong J; Shimoji M; Wang Y; Yuan J; Xiao X; Wang GX; Zou WQ
J Toxicol Environ Health A; 2011; 74(22-24):1493-503. PubMed ID: 22043910
[TBL] [Abstract][Full Text] [Related]
39. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
[TBL] [Abstract][Full Text] [Related]
40. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation.
Cordeiro Y; Machado F; Juliano L; Juliano MA; Brentani RR; Foguel D; Silva JL
J Biol Chem; 2001 Dec; 276(52):49400-9. PubMed ID: 11604397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
